(Q33745167)

29 July 2017

1 reference

title

Signaling antibodies in cancer therapy (English)

1 reference

29 July 2017

1 reference

Cragg MS

1

1 reference

29 July 2017

French RR

series ordinal

2

1 reference

29 July 2017

Glennie MJ

series ordinal

3

1 reference

29 July 2017

publication date

1 October 1999

1 reference

Current Opinion in Immunology

29 July 2017

published in

1 reference

29 July 2017

volume

11

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

541-547

1 reference

Antibody-based immunological therapies

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

Monoclonal antibody-based therapies for hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: emerging concepts of a tumour-targeted strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

Treatment of T-cell prolymphocytic leukemia with human CD52 antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

Human antibodies by design

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

Positive versus negative signaling by lymphocyte antigen receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

The association between CD20 and Src-family Tyrosine kinases requires an additional factor

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

Prevention of breast tumour development in vivo by downregulation of the p185neureceptor

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

The TRAIL to selective tumor death

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2899%2900010-2

7 January 2021

10.1016/S0952-7915(99)00010-2

Identifiers

DOI

1 reference

release_2nxyaivhzrcq3djjxkp6livy4e

29 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2nxyaivhzrcq3djjxkp6livy4e

24 November 2022

mapped directly with Wikidata item

1 reference